

## Full Portfolio Holdings\* as of March 31, 2025

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
<b>BASE CURRENCY</b>					
US DOLLAR			1,183,167	1,183,167	0.13%
<b>COMMON STOCKS</b>					
Eli Lilly & Co.			142,636	117,804,499	13.05%
UnitedHealth Group, Inc.			173,748	91,000,515	10.08%
Boston Scientific Corp.			425,673	42,941,892	4.76%
Merck & Co., Inc.			396,545	35,593,879	3.94%
Intuitive Surgical, Inc.			61,811	30,613,134	3.39%
Vertex Pharmaceuticals, Inc.			55,135	26,730,551	2.96%
Thermo Fisher Scientific, Inc.			50,583	25,170,101	2.79%
Johnson & Johnson			138,564	22,979,454	2.54%
Cencora, Inc.			81,562	22,681,577	2.51%
AbbVie, Inc.			105,446	22,093,046	2.45%
HCA Healthcare, Inc.			58,156	20,095,806	2.23%
AstraZeneca PLC			217,999	16,022,927	1.77%
Abbott Laboratories			118,304	15,693,026	1.74%
Waters Corp.			35,611	13,125,146	1.45%
Danaher Corp.			63,029	12,920,945	1.43%
Bristol-Myers Squibb Co.			210,744	12,853,277	1.42%
Gilead Sciences, Inc.			107,252	12,017,587	1.33%
Centene Corp.			197,936	12,016,695	1.33%
Humana, Inc.			36,233	9,587,252	1.06%
Argenx SE			16,140	9,552,701	1.06%
Molina Healthcare, Inc.			28,940	9,532,547	1.06%
ICON PLC			53,709	9,398,538	1.04%
Dexcom, Inc.			134,492	9,184,459	1.02%
Medtronic PLC			101,016	9,077,298	1.01%
Edwards Lifesciences Corp.			123,613	8,959,470	0.99%
Stryker Corp.			22,760	8,472,410	0.94%
Insulet Corp.			31,677	8,318,697	0.92%
Labcorp Holdings, Inc.			35,347	8,226,661	0.91%
UCB SA			44,715	7,872,728	0.87%
Galderma Group AG			74,304	7,858,738	0.87%
Encompass Health Corp.			76,224	7,719,967	0.85%
Agilent Technologies, Inc.			64,974	7,600,659	0.84%
Alignment Healthcare, Inc.			405,371	7,548,008	0.84%
Option Care Health, Inc.			214,782	7,506,631	0.83%
United Therapeutics Corp.			22,735	7,008,518	0.78%
Exact Sciences Corp.			161,697	6,999,863	0.78%
Novo Nordisk AS			98,689	6,748,186	0.75%
Elevance Health, Inc.			14,298	6,219,058	0.69%
Glaukos Corp.			62,733	6,174,182	0.68%
Acadia Healthcare Co., Inc.			203,387	6,166,694	0.68%

## Full Portfolio Holdings\* as of March 31, 2025

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Verona Pharma PLC			94,555	6,003,297	0.66%
LifeStance Health Group, Inc.			862,055	5,741,286	0.64%
Amgen, Inc.			18,097	5,638,120	0.62%
Daiichi Sankyo Co. Ltd.			233,030	5,549,346	0.61%
Alnylam Pharmaceuticals, Inc.			19,602	5,292,932	0.59%
Ascendis Pharma AS			32,180	5,015,575	0.56%
GSK PLC			262,042	5,007,671	0.55%
Avidity Biosciences, Inc.			164,164	4,846,121	0.54%
Revolution Medicines, Inc.			133,781	4,730,496	0.52%
Addus HomeCare Corp.			47,184	4,666,026	0.52%
Privia Health Group, Inc.			197,044	4,423,638	0.49%
Qiagen NV			109,473	4,395,341	0.49%
Elanco Animal Health, Inc.			394,668	4,144,014	0.46%
DiaSorin SpA			38,651	3,838,494	0.43%
Natera, Inc.			26,657	3,769,566	0.42%
Soleno Therapeutics, Inc.			51,957	3,712,328	0.41%
Surgery Partners, Inc.			153,789	3,652,489	0.40%
Ardent Health Partners, Inc.			256,976	3,533,420	0.39%
Merus NV			81,770	3,441,699	0.38%
Zai Lab Ltd.			93,366	3,374,247	0.37%
Scholar Rock Holding Corp.			103,132	3,315,694	0.37%
PTC Therapeutics, Inc.			62,761	3,198,301	0.35%
Align Technology, Inc.			19,807	3,146,540	0.35%
Ultragenyx Pharmaceutical, Inc.			85,594	3,099,359	0.34%
agilon health, Inc.			710,084	3,074,664	0.34%
Sarepta Therapeutics, Inc.			47,522	3,032,854	0.34%
Axsome Therapeutics, Inc.			25,045	2,920,998	0.32%
Cytokinetics, Inc.			70,887	2,848,949	0.32%
Blueprint Medicines Corp.			30,498	2,699,378	0.30%
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.			71,595	2,692,152	0.30%
Bio-Techne Corp.			44,430	2,604,931	0.29%
Evolent Health, Inc.			273,050	2,585,784	0.29%
Nuvalent, Inc.			35,871	2,543,971	0.28%
Xenon Pharmaceuticals, Inc.			74,004	2,482,834	0.27%
Vaxcyte, Inc.			65,611	2,477,471	0.27%
Akero Therapeutics, Inc.			60,434	2,446,368	0.27%
Disc Medicine, Inc.			48,531	2,409,079	0.27%
Hologic, Inc.			38,592	2,383,828	0.26%
Apogee Therapeutics, Inc.			62,503	2,335,112	0.26%
Crinetics Pharmaceuticals, Inc.			69,066	2,316,474	0.26%
Kymera Therapeutics, Inc.			70,746	1,936,318	0.21%
Structure Therapeutics, Inc.			109,775	1,900,205	0.21%
Apellis Pharmaceuticals, Inc.			84,844	1,855,538	0.21%
Astellas Pharma, Inc.			185,474	1,805,497	0.20%
Immunocore Holdings PLC			60,473	1,794,234	0.20%
Amicus Therapeutics, Inc.			215,167	1,755,763	0.19%

## Full Portfolio Holdings\* as of March 31, 2025

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
PACS Group, Inc.			153,261	1,722,654	0.19%
Celldex Therapeutics, Inc.			94,000	1,706,100	0.19%
Tecan Group AG			8,752	1,665,318	0.18%
Ionis Pharmaceuticals, Inc.			54,986	1,658,928	0.18%
Savara, Inc.			580,812	1,608,849	0.18%
Biogen, Inc.			11,747	1,607,459	0.18%
Spyre Therapeutics, Inc.			97,434	1,572,098	0.17%
Nurix Therapeutics, Inc.			131,845	1,566,319	0.17%
Rocket Pharmaceuticals, Inc.			189,918	1,266,753	0.14%
Newamsterdam Pharma Co. NV			57,269	1,172,296	0.13%
Arcus Biosciences, Inc.			149,195	1,171,181	0.13%
Janux Therapeutics, Inc.			28,886	779,922	0.09%
<b>FOREIGN CURRENCY</b>					
BRAZILIAN REAL			1,906,284	334,058	0.04%
DANISH KRONE			1,239	180	0.00%
EURO CURRENCY			117	126	0.00%
SWISS FRANC			12	14	0.00%
HONG KONG DOLLAR			37	5	0.00%
JAPANESE YEN			1	0.01	0.00%
<b>RIGHTS</b>					
Abiomed, Inc.			7,416	7,564	0.00%
<b>SHORT-TERM INVESTMENTS</b>					
Fixed Income Clearing Corp.		4/1/2025	297,001	297,001	0.03%
<b>TOTAL INVESTMENTS</b>				<b>903,845,710</b>	<b>100.09%</b>
<b>OTHER ASSETS LESS LIABILITIES</b>				<b>(853,644)</b>	<b>-0.09%</b>
<b>TOTAL NET ASSETS</b>				<b>902,992,066</b>	<b>100.00%</b>

\* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on [www.hartfordfunds.com](http://www.hartfordfunds.com) for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual report to shareholders filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT.

**Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting [hartfordfunds.com](http://hartfordfunds.com). Please read it carefully before investing.**

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

227833 03/22